HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS
摘要:
本发明涉及式(I)的杂双环化合物,其制备过程,含有它们的制药组合物以及它们作为药物的用途。
公开号:
US20100298289A1
作为产物:
描述:
methyl 2-oxo-4-phenylcyclohexanecarboxylate 、 碳酸胍 在
乙醇 、 水 作用下,
以
乙醇 为溶剂,
反应 18.0h,
以to afford the title compound in a 3:1 ratio of regioisomers by NMR as a brown solid (734 mg, 93%)的产率得到2-amino-7-phenyl-5,6,7,8-tetrahydroquinazolin-4-ol
参考文献:
名称:
HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS
[EN] HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS HÉTÉROBICYCLIQUES UTILES COMME ANTAGONISTES DU RÉCEPTEUR H4 DE L'HISTAMINE
申请人:UCB PHARMA SA
公开号:WO2009047255A1
公开(公告)日:2009-04-16
The present invention concerns heterobicyclic compounds of formula (I) processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
本发明涉及公式(I)的杂双环化合物,制备它们的方法,含有它们的药物组合物以及它们作为药物的用途。
HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS
申请人:Raphy Gilles
公开号:US20100298289A1
公开(公告)日:2010-11-25
The present invention concerns heterobicyclic compounds of formula (I) processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.